Replies to post #122551 on Amarin Corp Plc (AMRN)

[dmlcento]

Bio, who are you going to believe? This analyst or Whal and his Kaiser doctor who won't give him a Vascepa script? Whal says 15% is going to be bad, this analyst says it will be great. Who do you believe?

[couldbebetter]

Agreed, and I think Reduce-It will show a RRR of better than 20%. However,
I think a significant decline in mortality is the real important key number
as doctors will get more excited over a medication that has been proven to
save patient lives above and beyond standard of care. Repatha does not do
that despite a RRR of over 20%. Even if Vascepa shows a 5% mortality
benefit that is far better than what Repatha has. Then, compare the cost
of the two, ease of use, and side effects; Vascepa should win every time.